[Challenges for evaluating complex interventions: The example of lifestyle].

Lifestyle interventions potentially contribute to the prevention and treatment of a number of common chronic diseases, such as type 2 diabetes and obesity. Nobody questions the importance of a healthy lifestyle, but at the same time it is clear that the effectiveness of lifestyle interventions has often not been investigated in a randomized controlled study, whereas the randomized clinical trial (RCT) is the golden standard in clinical drug research. In this article we discuss the methodological (im)possibilities of using RCTs in evaluating the effects of lifestyle interventions.

Retrospective analysis on the effect of Reverse Diabetes2 Now on kidney function in patients with type 2 diabetes with impaired kidney function.

Objective: Type 2 diabetes is one of the main causes of kidney damage. Recent intervention studies suggest that the progression of type 2 diabetes can be halted, or even brought into remission by lifestyle interventions. In a pragmatic trial, the Reverse Diabetes2 Now programme (RD2N, NL: Keer Diabetes2 Om), a multicomponent lifestyle intervention, reduced the need for bloodglucose lowering medications up to 24 months.

Increased end-stage diabetic nephropathy in Indo-Asian immigrants living in the Netherlands.

Aims/hypothesis: We aimed to investigate the risk of end-stage diabetic nephropathy due to Type II (non-insulin-dependent) diabetes mellitus in Indo-Asian immigrants from Surinam.

Methods: A demographically based case-control study was carried out in Surinamese Indo-Asian immigrants and Dutch Caucasian subjects. All patients with end-stage diabetic nephropathy who had started dialysis between 1990 and 1998 were identified through a national registry of all patients entering a renal replacement program in the Netherlands.

Annual evaluation of hip joints and hands for radiographic signs of A beta 2M-amyloidosis in long-term hemodialysis patients.

Radiographs of hand and hip joints of 15 hemodialysis patients taken annually over at least 15 years were evaluated in this retrospective study. We looked for signs of A beta 2M-amyloidosis such as lucencies, erosions, and soft tissue swelling. The femoral head-soft tissue distance (FHSTD) was used to estimate the soft tissue swelling of the hips.